**Table S1.** ADR rate by weight and average adalimumab dose.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | Average adalimumab dose | |
|  | ADR by weight category\* | <40 mg q2w | ≥40 mg q2w |
| ADR by average dose\*\* | – | 38.8 (33/85) | 26.9 (73/271) |
| Weight category, kg | – | – | – |
| <20 | 46.9 (15/32) | 46.9 (15/32) | 0 |
| ≥20–<30 | 41.7 (20/48) | 41.5 (17/41) | 42.9 (3/7) |
| ≥30–<40 | 26.6 (17/64) | 25.0 (1/4) | 26.7 (16/60) |
| ≥40–<50 | 27.2 (28/103) | 0.0 (0/1) | 27.5 (28/102) |
| ≥50 | 28.8 (21/73) | 0 | 28.8 (21/73) |
| Unknown | 13.9 (5/36) | 0 | 13.9 (5/36) |
| ADR: adverse drug reaction; q2w: every 2 weeks.  Data are presented as % (n/N).  \**p* = .1120 (“Unknown” excluded); \*\**p* = .0418; *p* value was calculated by Fisher’s test. | | | |

**Table S2.** DAS28-4/ESR remission rate by weight and average adalimumab dose.

|  |  |  |  |
| --- | --- | --- | --- |
|  |  | Average adalimumab dose | |
|  | DAS28-4/ESR remission by weight category\* | <40 mg q2w | ≥40 mg q2w |
| DAS28-4/ESR remission by average dose\*\* |  | 61.4 (27/44) | 74.2 (118/159) |
| Weight category, kg | – | – | – |
| <20 | 66.7 (12/18) | 66.7 (12/18) | 0 |
| ≥20–<30 | 60.7 (17/28) | 59.1 (13/22) | 66.7 (4/6) |
| ≥30–<40 | 64.1 (25/39) | 50.0 (1/2) | 64.9 (24/37) |
| ≥40–<50 | 74.2 (49/66) | 0.0 (0/1) | 75.4 (49/65) |
| ≥50 | 81.0 (34/42) | – | 81.0 (34/42) |
| Unknown | − | 100.0 (1/1) | 77.8 (7/9) |
| DAS28-4/ESR: 4-variable Disease Activity Score in 28 joints using erythrocyte sedimentation rate; q2w: every 2 weeks.  Data are presented as % (n/N).  \**p* = .2864 (“Unknown” excluded); \*\**p* = .1304; *p* value was calculated by Fisher’s test. | | | |

**Table S3.** Change in effectiveness parameters (effectiveness population).

|  |  |  |  |  |  |  |  |  |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
|  |  | Change from baseline | | | | | | |
| Effectiveness parameter | Baseline | | Week 4 | Week 8 | Week 12 | Week 16 | Week 24 | Last evaluation time point |
| Number of tender joints | *n* = 188 | | *n* = 180 | *n* = 153 | *n* = 154 | *n* = 167 | *n* = 158 | *n* = 188 |
| 3.8 (4.2) | | −1.9 (3.1)\* | −2.5 (3.5)\* | −2.5 (3.5)\* | −2.8 (3.6)\* | −2.8 (4.0)\* | −2.8 (4.1)\* |
| Number of swollen joints | *n* = 187 | | *n* = 179 | *n* = 154 | *n* = 153 | *n* = 166 | *n* = 157 | *n* = 187 |
| 3.7 (4.2) | | −1.7 (3.1)\* | −2.4 (3.7)\* | −2.4 (3.7)\* | −2.6 (4.2)\* | −2.6 (4.2)\* | −2.6 (4.1)\* |
| Patient-assessed VAS, mm | *n* = 175 | | *n* = 160 | *n* = 135 | *n* = 136 | *n* = 143 | *n* = 138 | *n* = 175 |
| 37.3 (27.1) | | −12.9 (18.4)\* | −16.4 (22.7)\* | −16.8 (24.9)\* | −20.1 (25.4)\* | −22.1 (29.1)\* | −21.3 (29.0)\* |
| Physician-assessed VAS, mm | *n* = 166 | | *n* = 150 | *n* = 129 | *n* = 129 | *n* = 133 | *n* = 133 | *n* = 164 |
| 39.9 (25.0) | | −15.1 (20.7)\* | −20.4 (23.0)\* | −20.7 (25.2)\* | −24.3 (24.3)\* | −26.1 (27.7)\* | −24.6 (27.7)\* |
| ESR, mm/h | *n* = 180 | | *n* = 165 | *n* = 140 | *n* = 140 | *n* = 154 | *n* = 143 | *n* = 180 |
| 21.9 (21.1) | | −9.3 (17.6)\* | −10.7 (19.3)\* | −9.8 (20.2)\* | −9.9 (20.0)\* | −10.7 (20.3)\* | −9.5 (19.5)\* |
| CRP, mg/dL | *n* = 186 | | *n* = 175 | *n* = 146 | *n* = 151 | *n* = 161 | *n* = 154 | *n* = 186 |
| 1.169 (2.129) | | −0.608 (2.107)\*\* | −0.759 (2.094)\* | −0.797 (1.979)\* | −0.721 (2.092)\* | −0.900 (1.953)\* | −0.808 (1.995)\* |
| All values are mean (SD); \**p* < .0001; \*\**p* = .0001.  CRP: C-reactive protein; ESR: erythrocyte sedimentation rate; SD: standard deviation; VAS visual analog scale. | | | | | | | | |